This is a working overview of DAC linker, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
26 February: A wildfire engulfs over 70 hectares of land near Waipoua Settlement, leading to the evacuation of local residents. Justice Minister Paul Goldsmith and Associate Justice Minister Nicole McKee confirm the Government will introduce legislation expanding citizen's arrest powers that they claim will combat retail crime. Foreign Minister Winston Peters met with Chinese Foreign Minister Wang Yi to raise concerns about Chinese naval exercises in the Tasman Sea. Police confirm they have issued a warrant to arrest a 44-year old man in connection with the arson of four Masterton churches on 22 February. 27 February – The New Zealand Government confirms it will introduce legislation to extend the parliamentary term from three to four years, subject to a referendum. 28 February: High Court Justice Simon Moore quashes Whakaari Management Limited's conviction for its role in the 2019 Whakaari / White Island eruption. Sarah Fitt resigns as chief executive of state pharmaceutical agency Pharmac. Oranga Tamariki workers affiliated with Public Service Association launch a seven-week strike avoiding double shifts, being on-call, and working overtime to protest unsatisfactory pay and work conditions.
Nanomaterials are used in a variety of, manufacturing processes, products and healthcare including paints, filters, insulation and lubricant additives. In healthcare Nanozymes are nanomaterials with enzyme-like characteristics. They are an emerging type of artificial enzyme, which have been used for wide applications in such as biosensing, bioimaging, tumor diagnosis, antibiofouling and more. High quality filters may be produced using nanostructures, these filters are capable of removing particulate as small as a virus as seen in a water filter created by Seldon Technologies. Nanomaterials membrane bioreactor (NMs-MBR), the next generation of conventional MBR, are recently proposed for the advanced treatment of wastewater. In the air purification field, nano technology was used to combat the spread of MERS in Saudi Arabian hospitals in 2012. Nanomaterials are being used in modern and human-safe insulation technologies; in the past they were found in Asbestos-based insulation. As a lubricant additive, nanomaterials have the ability to reduce friction in moving parts. Worn and corroded parts can also be repaired with self-assembling anisotropic nanoparticles called TriboTEX. Nanomaterials have also been applied in a range of industries and consumer products. Mineral nanoparticles such as titanium-oxide have been used to improve UV protection in sunscreen. In the sports industry, lighter bats to have been produced with carbon nanotubes to improve performance.
== Release == In June 2013, the U.S. distribution rights for That Awkward Moment were acquired by FilmDistrict with a wide release set for January 31, 2014. Because of a transition of FilmDistrict properties to Focus Features, That Awkward Moment was later absorbed by the reconstituted Focus Features for its January 2014 release. The first red band trailer was released on October 14, 2013.
Palominos have a chestnut base coat color that is genetically modified to a golden shade by a single copy of the incomplete dominant cream gene. Palominos can be distinguished from chestnuts by the lack of true red tones in the coat; even the palest chestnuts have slight red tints to their hair rather than gold. The eyes of chestnuts are usually dark brown, while those of a palomino are sometimes a slightly lighter amber. Some color breed registries that promote palomino coloring have accepted flaxen chestnuts because registration is based on a physical description rather than a genetic identity. Cremellos have a chestnut base coat and homozygous (two copies) for the cream gene. They have a cream-colored coat, blue eyes and lightly pigmented pink skin. Red duns have a chestnut base coat with the dun gene (one or two copies). Their body color is pale, dusty tan shade that resembles the light undercoat color of a body-clipped chestnut but with a bold, dark dorsal stripe in dark red, a red mane, tail and legs. They may have additional primitive markings, which distinguish a red dun from a light or body-clipped chestnut. Gold champagnes have a chestnut base coat with the champagne gene (one or two copies). They resemble a palomino, or they may be an all-over apricot shade, but can be distinguished from other colors by amber or green eyes and lightened skin color with freckling. Red or "strawberry" roans have a chestnut base coat with the classic roan gene (one or two copies). A skewbald, "chestnut pinto" or "sorrel Paint" is a pinto horse with chestnut and white patches.
Sources: en.wikipedia.org
== External links == Human ACTB genome location and ACTB gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P60709 (Actin, cytoplasmic 1) at the PDBe-KB.
== Pharmacokinetics == Epelsiban has a good Cyp450 profile with no significant inhibition IC50 > 100μM together with no time-dependent inhibition observed against the five Cyp450 isozymes (1A2, 2C9, 2C19. 2D6, 3A4 DEF, 3A4 7BQ). In addition, Epelsiban has low intrinsic clearance in all four species (rat, dog. cyno monkey, human), a good PK profile in the rat with a bioavailability of 55%, oral exposure and bioavailability in the cynomolgus monkey comparable to retosiban, and good aqueous solubility (33 mg/ml as the besylate salt).
The fur is soft, with dense underfur and long, coarse, thick guard hairs. The fur is not as shaggy or coarse as that of brown bears. American black bear skins can be distinguished from those of Asian black bears by the lack of a white blaze on the chest and hairier footpads. Despite their name, black bears show a great deal of color variation. Individual coat colors can range from white, blonde, cinnamon, light brown or dark chocolate brown to jet black, with many intermediate variations existing. Silvery-gray American black bears with a blue luster (found mostly on the flanks) occur along a portion of coastal Alaska and British Columbia. White to cream-colored American black bears occur in the coastal islands and the adjacent mainland of southwestern British Columbia. Albino individuals have also been recorded. Black coats tend to predominate in humid areas, such as Maine, New England, New York, Tennessee, Michigan and western Washington. Approximately 70% of all American black bears are black, though only 50% in the Rocky Mountains are black. Many in northwestern North America are cinnamon, blonde or light brown in color and thus may sometimes be mistaken for grizzly bears. Grizzly (and other types of brown) bears can be distinguished by their shoulder hump, larger size and broader, more concave skull. In his book The Great Bear Almanac, Gary Brown summarized the predominance of black or brown/blonde specimens by location:
=== Seizures === Phenobarbital is used in the treatment of all types of seizures, except absence seizures. It is no less effective at seizure control than phenytoin, but phenobarbital is not as well tolerated. Phenobarbital may provide a clinical advantage over carbamazepine for treating partial seizures. Carbamazepine may provide a clinical advantage over phenobarbital for generalized tonic–clonic seizures. The first-line drugs for treatment of status epilepticus are benzodiazepines, such as lorazepam, clonazepam, midazolam, or diazepam. If these fail, then phenytoin may be used, with phenobarbital being an alternative in the US (favored in infants), but used only third-line in the UK. Failing that, the only treatment is anesthesia in intensive care. The World Health Organization (WHO) gives phenobarbital a first-line recommendation in the developing world and it is commonly used there. Phenobarbital is the first-line choice for the treatment of neonatal seizures. Concerns that neonatal seizures in themselves could be harmful make most physicians treat them aggressively. However, no reliable evidence supports this approach.
Breastmilk may be stored for various amounts of time depending on storage temperature and conditions. The content and quality of expressed milk change over time as it is stored, particularly when frozen. For example, there is a decrease in the ability of breastmilk to kill bacteria when it is stored in the refrigerator for more than 48 hours. Additionally, the quantity of fat, protein, and calories in breastmilk decreases when the milk is frozen for more than 3 months. While several components of breastmilk change over time, inflammatory factors (cytokines) and maternal antibodies, and growth factors are thought to be stable for at least 6 months when the breastmilk is frozen. Storage guidelines, according to the CDC, La Leche League International and the Academy of Breastfeeding Medicine, are noted in the table below.
Sources: en.wikipedia.org
As topiramate inhibits carbonic anhydrase, use with other inhibitors of carbonic anhydrase (e.g., acetazolamide) increases the risk of kidney stones. Enzyme inducers (e.g., carbamazepine) can increase the elimination of topiramate, possibly necessitating dose escalations of topiramate. Topiramate may increase the plasma levels of phenytoin. Topiramate itself is a weak inhibitor of CYP2C19 and induces CYP3A4; a decrease in plasma levels of estrogens and digoxin has been noted during topiramate therapy. This can reduce the effectiveness of oral contraceptives (i.e., birth control pills); use of alternative birth control methods is recommended. Neither intrauterine devices (IUDs) nor Depo-Provera are affected by topiramate. Alcohol may cause increased sedation or drowsiness and increase the risk of having a seizure. As topiramate may result in acidosis, other treatments that also do so may worsen this effect. Oligohidrosis and hyperthermia were reported in post-marketing reports about topiramate; antimuscarinic drugs (like trospium) can aggravate these disorders.
The goal of substituting DNA by XNA may also be reached by another route, namely by engineering the environment instead of the genetic modules. This approach has been successfully demonstrated by Marlière and Mutzel with the production of an E. coli strain whose DNA is composed of standard A, C and G nucleotides but has the synthetic thymine analogue 5-chlorouracil instead of thymine (T) in the corresponding positions of the sequence. These cells are then dependent on externally supplied 5-chlorouracil for growth, but otherwise they look and behave as normal E. coli. These cells, however, are currently not yet fully auxotrophic for the Xeno-base since they are still growing on thymine when this is supplied to the medium.
In early 1945, P-51C, D, and K variants also joined the Chinese Nationalist Air Force. These Mustangs were provided to the 3rd, 4th, and 5th Fighter Groups and used to attack Japanese targets in occupied areas of China. The P-51 became the most capable fighter in China, while the Imperial Japanese Army Air Force used the Nakajima Ki-84 Hayate against it. The P-51 was a relative latecomer to the Pacific theater, due largely to the need for the aircraft in Europe, plus the P-38 was already successful in the Pacific since its twin-engined design was considered a safety advantage for long, over-water flights. The first P-51s were deployed in the Far East later in 1944, operating in close-support and escort missions, as well as tactical photoreconnaissance. As the war in Europe wound down, the P-51 became more common in the Far East. With the capture of Iwo Jima, USAAF P-51 Mustang fighters of the VII Fighter Command were stationed on that island starting in March 1945, being initially tasked with escorting Boeing B-29 Superfortress missions against the Japanese homeland. Iwo Jima's extreme humidity and blowing volcanic dust made aircraft maintenance challenging. To achieve the range required on very-long range missions, the P-51's engine was operated for very long periods at minimum power settings, leading to lead fouling of the spark plugs which had to be replaced after each mission. P-51s would fly round trips of 1,500 miles, mostly flown over water with minimal navigation equipment, and these escort missions would take seven or eight hours.
Most notable was a large emphasis on partnerships and collaborations to ensure that the majority of PSI research is focused on proteins of interest to the broader research community as well as efforts to make PSI products more accessible to the research community. Grant applications for PSI:Biology were submitted by October 29, 2009. See Phase 3 section above.
=== Blocking of L-type calcium channels === Because the presence of calcium in the cytosol is required for muscle contraction, blockers of calcium channels prevent the muscles from building tension. Blockers of the L-type calcium channels, which occur in cardiac and smooth muscles, thus act as smooth muscle relaxants and inhibitors of cardiac contractions. Common blockers of L-type calcium channels are 1,4-dihydropyridines, which are used in treatment of cardiovascular diseases. Because of their activity as a relaxant, they can relax smooth muscles surrounding blood vessels, thus widening them and lowering the blood pressure.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.